Quotient Investors’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Quotient Investors’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-7,000	Closed	-$204K	–	295
2014 Q2	$204K	Buy	+7,000	New	+$169K	0.04%	229

Other funds holding PTLA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

Quotient Investors's PTLA Position: Q3 2014 in Review

Quotient Investors sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q3 2014, closing a stake of 7,000 shares — an estimated $204K sold.

Quotient Investors first reported a position in PTLA in Q2 2014 and held it in 1 quarter. The position peaked at $204K in Q2 2014. 108 funds tracked by Wall St. Rank hold PTLA as of Q3 2014.

Quotient Investors reported no remaining Portola Pharmaceuticals, Inc. position as of Q3 2014 after selling out during the quarter.
Quotient Investors sold 7,000 Portola Pharmaceuticals, Inc. shares in Q3 2014, an estimated $204K.
Quotient Investors first reported a position in Portola Pharmaceuticals, Inc. in Q2 2014 and held it in 1 quarter.
Quotient Investors's Portola Pharmaceuticals, Inc. position peaked at $204K in Q2 2014.
108 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2014.

Based on Quotient Investors's 13F filing for Q3 2014, filed 14 Oct 2014.